Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
11/2007
11/08/2007US20070259816 Expression vector comprising nucleotide sequences coding homeobox gene for use in identifying modulators for treatment and prevention of nervous system and seizure disorders
11/08/2007US20070259811 Method of modulating the proliferation of medullary thyroid carcinoma cells
11/08/2007US20070259035 Colored liquid-filled soft capsules and method of manufacture thereof
11/08/2007US20070259007 Lactoferrin: an adjuvant for vaccines
11/08/2007US20070259003 Clostridial toxin derivatives and methods for treating pain
11/08/2007US20070258989 Immunomodulatory pharmaceutical composition and a process for preparation thereof
11/08/2007US20070258986 Targeted Delivery System for Bioactive Agents
11/08/2007US20070258982 Methods of using antibodies against human IL-22
11/08/2007US20070258980 Vascular endothelial cell growth factor antagonists and uses thereof
11/08/2007US20070258973 Diagnostics and Therapeutics for Diseases Associated with Tripeptidyl-Peptidase 2(Tpp2)
11/08/2007US20070258897 Antibodies Against Bacterial Antigens and Their Use in the Generation of Immune Responses Against Apoptotic Cells
11/08/2007DE60021370C5 Piperazinderivate verwendbar als ccr5 antagonisten Piperazine derivatives useful as antagonists ccr5
11/08/2007CA2650683A1 Amine derivative having npy y5 receptor antagonist activity
11/08/2007CA2650589A1 Antisecretory protein for the treatment of compartment syndrome
11/08/2007CA2650577A1 Use of 12-imidazolyl-1-dodecanol or its pharmaceutically acceptable salts for producing a pharmaceutical preparation
11/08/2007CA2650572A1 Novel aminopyridine derivatives having aurora a selective inhibitory action
11/08/2007CA2650119A1 Dihydropyrazolopyrimidinone derivatives
11/08/2007CA2648898A1 Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof
11/08/2007CA2647359A1 Tumor cell differentiation agents as chemical inhibitors and treatments for intracellular parasites
11/07/2007EP1852505A1 Mutations in ion channels
11/07/2007EP1852439A1 Spiroketal derivative and use thereof as diabetic medicine
11/07/2007EP1852432A1 Nitrogenous heterocyclic compound and medicinal use thereof
11/07/2007EP1852430A1 Method of producing proanthocyanidin oligomer
11/07/2007EP1852128A1 An anti HSP90 antibody
11/07/2007EP1852124A1 Fibrosis inhibitor for implanted organ
11/07/2007EP1852121A2 Lipid analogs for treating viral infections
11/07/2007EP1852120A1 Ointment
11/07/2007EP1852118A1 Method for producing adsorptive porous body
11/07/2007EP1852116A1 Pharmaceutical compositions of amlodipine and atorvastatin
11/07/2007EP1852114A1 COMPOSITION CONTAINING DIHOMO-(gamma)-LINOLENIC ACID (DGLA) AS THE ACTIVE INGREDIENT
11/07/2007EP1852113A2 Methods for treating neuropsychiatric disorders with NMDA receptors antagonists
11/07/2007EP1851739A2 Xanthurenic acid derivative pharmaceutical compositoins and methods related thereto
11/07/2007EP1851240A2 Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
11/07/2007EP1553831A4 Process for screening fungitoxic compounds
11/07/2007EP1523486B1 Tetracyclic arylsulfonyl indoles having serotonin receptor affinity
11/07/2007EP1513526B1 Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hppar activators
11/07/2007EP1400521B1 Piperazine compounds
11/07/2007EP1192151B1 Anilinoquinazolines as protein tyrosine kinase inhibitors
11/07/2007EP1161687B1 Grb7 family proteins and the insulin receptor for screening novel medicines.
11/07/2007EP1144671B1 Enriched central nervous system cell populations
11/07/2007EP1042288B1 Tripeptidyl peptidase inhibitors
11/07/2007EP1003379B1 Novel phytase
11/07/2007CN200970353Y Medicinal plast for treating child spontaneous perspiration
11/07/2007CN101068772A N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds
11/07/2007CN101068560A Method of screening toxin-neutralizing peptide, STX2 inhibitory peptide and Vero toxin-neutralizing agent
11/07/2007CN101068556A Pilose antler nano-products containing enriched insulin-like growth factor and producing method thereof
11/07/2007CN101068543A Use of substituted cyclopropane acid derivative in treating metabolic syndrome medicine
11/07/2007CN101067135A Novel oligonucleotides and use of oligonucleotides modulating the expression of enzymes involved in the synthesis of melanic pigments, as depigmentation agents
11/07/2007CN101066997A Human antibodies that bind human IL-12 and methods for producing
11/07/2007CN101066439A Wind dispelling and obstruction eliminating capsule and its prepn
11/07/2007CN101066438A Hiccup treating medicine and its prepn process
11/07/2007CN101066319A Chinese medicine composition for treating flaccidity syndrome
11/07/2007CN101066313A Chinese medicine prepn for antagonizing bacteria and viruses of pig and improving pork quality and its prepn process
11/07/2007CN100347170C Azabicyclo-octane and nonane derivatives with DPP-IV inhibiting activity
11/07/2007CN100347167C Process for producing substituted 2-(2-pyridylmethye)sulfinye-1H-benzinmidazoles
11/07/2007CN100347162C N－苯基－2－嘧啶胺衍生物 N- phenyl-2-pyrimidine-amine derivative
11/07/2007CN100347158C Bicyclic compound
11/07/2007CN100347152C Benzamide or phenylacetamide derivatives useful as thyroid receptor ligands
11/07/2007CN100346850C Medicine coating rack
11/07/2007CN100346834C Vector for gene therapy and method of quantifying target protein in mammal or cultured cells with the administration of the vector for gene theraphy
11/07/2007CN100346825C Method of vaccination of newly hatched poultry
11/07/2007CN100346823C Enamel matrix protein compositions for modulating immune response
11/07/2007CN100346822C Leukocyte inactivation module
11/07/2007CN100346805C Application of shinyleaf yellowhorn fruit shell in preparing cerbral function improving food and medicine
11/07/2007CN100346792C Benzothiazole derivatives as adenosine receptor ligands
11/07/2007CN100346790C Application of (+) North America coptisine
11/07/2007CN100346789C Use of nk-1 receptor antagonists for the treatment of brain, spinal or nerve injury
11/07/2007CN100346786C Substituted benzimidazole compounds and their use for the treatment of cancer
11/07/2007CN100346782C Vitamin C composition containing amino acids
11/07/2007CN100346776C Remedies
11/06/2007USRE39916 Compounds that modulate PPAR activity and methods for their preparation
11/06/2007US7291732 Isomeric fused pyrrolocarbazoles and isoindolones
11/06/2007US7291731 7-(3-Pyridyl)-1,7-diazaspiro-[4,4]nonane and its salts and proline amides; capable of affecting nicotinic cholinergic receptors, e.g., as modulators of specific nicotinic receptor subtypes; neuroprotective agents
11/06/2007US7291650 Breast cancer ; therapy containing plant extracts
11/06/2007US7291644 For therapy and prophylaxis of allergic disorder, diseases accompanied with itching, secondary diseases generated by behaviors caused by itching, inflammation, chronic obstructive pulmonary disease, ischemic reperfusion disorder, pleuritis complicated by rheumatoid arthritis, cerebrovascular disease
11/06/2007US7291637 4,7-Methano--, ethano-, oxy- or thio- indazol-3-ones or benzisothiazol-3-ones in which the S is mono- or dioxygenated, e.g., 3a,4,7,7a-tetrahydro-4,7-methano-1,2-benzisothiazol-3(2H)-one-1,1-dioxide; treatment of diseases such as cancer and immune disorders
11/06/2007US7291635 Protein tyrosine phosphatase 1B inhibitors alone or incombination with other antidiabetic, antilipemic, anticholesterol or hypotensive agents
11/06/2007US7291634 N-substituted-benzyl-N-(hydroxyaminocarbonylmethyl)cycloalkyl(alk)oxybenzenesulfonamides, e.g., 2-[(cyclopropylmethoxy-benzenesulfonyl)-(4-[1,2,3]triazol-1-yl-benzyl)-amino]-N-hydroxy-acetamide; treating diseases mediated by matrix-degrading metalloproteinases, in particular hyperproliferative diseases
11/06/2007US7291633 nicotinic alpha 7 receptor and 5-HT3 or 5-HT6 receptor; control of cholinergic and dopaminergic neurotransmission; disorders of the central nervous system and serotonergic hyperactivity; psychiatric and neurodegenerativce disorders; antiemetics during chemotherapy
11/06/2007US7291630 Azaindoles as inhibitors of c-Jun N-terminal kinases
11/06/2007US7291624 Enzyme inhibitors as drugs for cardiovascular disorders, aids, alzheimers disease or urogenital disorders
11/06/2007US7291619 Melanocortin receptor agonists
11/06/2007US7291613 Inhibitors of p38 kinase
11/06/2007US7291610 Estrogenic compounds as anti-mitotic agents
11/06/2007US7291608 Anti-inflammatory 17.β.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.α
11/06/2007US7291499 Transformed cell, method of screening anti-aging agent and anti-aging agent
11/06/2007US7291495 β-Secretase variant
11/06/2007US7291458 Leptin-mediated gene-induction
11/06/2007US7291451 Modulation of pericyte proliferation
11/06/2007US7291347 Solubility, permeability, and bioavailability; oral dosage
11/06/2007US7291332 Inflammatory mediator antagonists
11/06/2007US7291330 MD-1 inhibitors as immune suppressants
11/06/2007CA2427576C Benzodiazepine derivatives as gaba a receptor modulators
11/06/2007CA2388564C Caspase inhibitor
11/06/2007CA2385538C Recombinant adenoviral vectors and their utilization in the treatment of various types of hepatic, renal and pulmonary fibrosis and hypertrophic scars
11/06/2007CA2241666C Tricyclic compounds, their production and use
11/06/2007CA2212129C A method of preparing mixed glucosamine salts
11/06/2007CA2182795C Superactive vip antagonists
11/06/2007CA2170236C Inducing antibody response against self-proteins with the aid of foreign t-cell epitopes
11/06/2007CA2113089C Universal donor cells
1 ... 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 ... 1564